Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Ps Multiple | 1.7x - 1.9x | 1.8x |
| Selected Fwd Ps Multiple | 1.5x - 1.7x | 1.6x |
| Fair Value | €10.38 - €11.47 | €10.93 |
| Upside | 23.9% - 37.0% | 30.4% |
| Benchmarks | Ticker | Full Ticker |
|---|---|---|
| Daiichi Sankyo Company, Limited | 456,800.0% | TSE:4568 |
| Kubota Pharmaceutical Holdings Co., Ltd. | 459,600.0% | TSE:4596 |
| Takeda Pharmaceutical Company Limited | 450,200.0% | TSE:4502 |
| Moberg Pharma AB (publ) | - | OM:MOB |
| Cumberland Pharmaceuticals Inc. | - | NasdaqGS:CPIX |
| Astellas Pharma Inc. | - | DB:YPH |
| Select Price / LTM Sales Ratio | ||||||||
| Benchmark Companies | ||||||||
| 4568 | 4596 | 4502 | MOB | CPIX | YPH | |||
| TSE:4568 | TSE:4596 | TSE:4502 | OM:MOB | NasdaqGS:CPIX | DB:YPH | |||
| Historical Sales Growth | ||||||||
| 5Y CAGR | 14.0% | NM- | 6.8% | -20.6% | 1.9% | 8.0% | ||
| 3Y CAGR | 21.8% | NM- | 8.7% | NM- | 1.7% | 13.8% | ||
| Latest Twelve Months | 17.8% | -24.6% | 7.5% | 1468.3% | 5.8% | 19.2% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 9.9% | -14787.5% | 6.6% | -3003.4% | -12.8% | 6.6% | ||
| Prior Fiscal Year | 12.5% | -3817.9% | 3.4% | NA | -15.9% | 1.1% | ||
| Latest Fiscal Year | 15.7% | -4933.3% | 2.4% | -2600.3% | -17.1% | 2.7% | ||
| Latest Twelve Months | 15.7% | -4247.5% | 2.4% | -1954.8% | -8.0% | 2.7% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 15.5x | -1.4x | 9.4x | -0.5x | 31.9x | 7.0x | ||
| Price / LTM Sales | 3.6x | 97.3x | 1.5x | 32.6x | 1.3x | 1.4x | ||
| LTM P/E Ratio | 22.9x | -2.3x | 63.6x | -1.7x | -16.3x | 52.5x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/S Ratio | 1.3x | 3.6x | 97.3x | |||||
| Historical LTM P/S Ratio | 1.4x | 2.3x | 2.7x | |||||
| Selected Price / Sales Multiple | 1.7x | 1.8x | 1.9x | |||||
| (x) LTM Sales | 1,912,323 | 1,912,323 | 1,912,323 | |||||
| (=) Equity Value | 3,238,155 | 3,408,585 | 3,579,014 | |||||
| (/) Shares Outstanding | 1,790.3 | 1,790.3 | 1,790.3 | |||||
| Implied Value Range | 1,808.71 | 1,903.91 | 1,999.10 | |||||
| FX Rate: JPY/EUR | 172.5 | 172.5 | 172.5 | Market Price | ||||
| Implied Value Range (Trading Cur) | 10.48 | 11.04 | 11.59 | 8.38 | ||||
| Upside / (Downside) | 25.2% | 31.8% | 38.3% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | 4568 | 4596 | 4502 | MOB | CPIX | YPH | |
| Value of Common Equity | 6,787,264 | 2,862 | 6,861,229 | 416 | 53 | 2,586,933 | |
| (/) Shares Outstanding | 1,862.6 | 58.4 | 1,579.1 | 47.0 | 15.0 | 1,790.3 | |
| Implied Stock Price | 3,644.00 | 49.00 | 4,345.00 | 8.86 | 3.56 | 1,444.96 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 172.51 | |
| Implied Stock Price (Trading Cur) | 3,644.00 | 49.00 | 4,345.00 | 8.86 | 3.56 | 8.38 | |
| Trading Currency | JPY | JPY | JPY | SEK | USD | EUR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 172.51 | |